Medical
-
According to a new report by the National Center for Health Statistics of the US Center for Disease Control (CDC), the 2009 US asthma rate rose to 8.2% of the population, a historic high. The… Read more . . .
-
Almirall and Forest Laboratories have announced that Phase 3 studies of inhaled aclidinium and Phase 2b studies of an inhaled aclidinium/formoterol combination both met their primary endpoints. As a result, the companies expect to submit… Read more . . .
-
Contract manufacturer Ritedose has voluntarily recalled unit dose vials of albuterol inhalation solution due to mislabeling. The single dose vials contain a 2.5 mg/3 mL solution but are labeled as 0.5 mg/3 mL. The product… Read more . . .
-
The results from Inspire Pharmaceuticals’ second Phase 3 trial of denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis show that the drug failed to meet its primary endpoint, change in FEV from baseline.… Read more . . .
-
According to MAP Pharmaceuticals, it has completed a year-long open label safety trial of its Levadex inhaled dihydroergotamine, the final step in its development program for the product. More than 250 patients completed the 12-month… Read more . . .
-
According to Pearl Therapeutics, a Phase 2b study has demonstrated that its PT003 glycopyrrolate/formoterol combination MDI provides superior bronchodilation compared to placebo, compared to its individual components, and compared to tiotropium. The trial involved patients… Read more . . .
-
Verona Pharma, which has been looking for a partner for its lead product RPL554, an inhaled phosphodiesterase 3 and phosphodiesterase 4 inhibitor for the treatment of asthma, COPD, and allergic rhinitis, announced that it has… Read more . . .
-
An article published in The Lancet on November 20, 2010 describes the case of a teen-aged boy who appeared to suffer from asthma exacerbations linked to emotional distress caused by his use of Facebook. His… Read more . . .
-
Researchers from the Medco Research Institute presented data at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) showing that clinicians are prescribing ICS/LABA combination treatment for two thirds of… Read more . . .
-
Having recently announced that it stands by its clinical trials after a former executive filed suit against the company for retaliatory termination after he raised concerns about the validity of studies conducted in Russia and… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK

